Back to Search
Start Over
Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics
- Source :
- The Journal of clinical endocrinology and metabolism. 91(9)
- Publication Year :
- 2006
-
Abstract
- Background: We have previously demonstrated an early and potent antiinflammatory effect of troglitazone and rosiglitazone. Hypothesis: Because inflammatory mediators interfere with insulin signal transduction, we have now hypothesized that rosiglitazone exerts an initial antiinflammatory effect independently of its metabolic actions including the suppression of the plasma concentration of free fatty acids (FFAs), insulin, and glucose after which insulin sensitization occurs. Patient and Methods: Fourteen patients with type 2 diabetes were included in the study. Eight patients were given 2 mg daily of rosiglitazone for 6 wk, whereas the other six patients were given a placebo for the same period. Results: After a 2-mg dose of rosiglitazone, plasma FFAs, insulin, and glucose concentrations and homeostasis model assessment of insulin resistance did not change. Plasma C-reactive protein, serum amyloid A, and matrix metalloproteinase concentrations fell significantly at wk 1 and continued to be significantly lower than the baseline levels by 25, 29, and 24%, respectively, at wk 6. Leukocyte count was significantly lower at wk 6 after rosiglitazone, whereas there was no change in the control group. Plasma adiponectin concentrations increased significantly at wk 2 and continued to increase during the treatment period with rosiglitazone. Resistin concentrations fell significantly by 10% at wk 6 only. There were no changes in any of these indices in the placebo group. Conclusions: A low dose of rosiglitazone exerts an early and potent antiinflammatory effect with an increase in adiponectin and a fall in resistin concentrations without causing any metabolic changes (fall in plasma glucose, FFAs, and insulin concentrations) over a 6-wk period. The increase in adiponectin and the decrease in resistin after rosiglitazone are thus related primarily to its antiinflammatory effects rather than its metabolic actions. These observations have implications in relation to the mode of action of this drug as an insulin-sensitizing agent and also its use as a potential antiinflammatory and antiatherogenic drug in the future.
- Subjects :
- Blood Glucose
Male
medicine.medical_specialty
Endocrinology, Diabetes and Metabolism
medicine.medical_treatment
Clinical Biochemistry
Type 2 diabetes
Fatty Acids, Nonesterified
Biochemistry
Rosiglitazone
Leukocyte Count
Endocrinology
Insulin resistance
Diabetes mellitus
Internal medicine
medicine
Humans
Hypoglycemic Agents
Insulin
Resistin
Obesity
Serum Amyloid A Protein
Adiponectin
Dose-Response Relationship, Drug
business.industry
Biochemistry (medical)
Troglitazone
Middle Aged
medicine.disease
C-Reactive Protein
Diabetes Mellitus, Type 2
Matrix Metalloproteinase 9
Female
Thiazolidinediones
Insulin Resistance
business
medicine.drug
Subjects
Details
- ISSN :
- 0021972X
- Volume :
- 91
- Issue :
- 9
- Database :
- OpenAIRE
- Journal :
- The Journal of clinical endocrinology and metabolism
- Accession number :
- edsair.doi.dedup.....d864dada351fa0ebac739c183ffc1cb0